International Hepatology Archives - Page 44 of 47

AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B

By Mourabit Halima 2023.12.21

From November 10th to 14th, 2023, the annual highlight in the field of hepatology—the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was grandly held in Boston, USA. Dr. Zhenhuan Cao from Beijing You'an Hospital, Capital Medical University, as the corresponding author, presented a research abstract at the conference, revealing the influence of hepatic steatosis on the efficacy of antiviral therapy in patients with chronic hepatitis B (CHB). The results suggest that hepatic steatosis has no significant impact on the effectiveness of nucleos(t)ide analogs (NAs) and pegylated interferon (PEG-IFN) treatment [1]. Hepatology Digest reports on this, and the relevant content is shared below.

Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

By Peter W. PENG 2023.12.21

Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The "Sprout" project is China's first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang's team, with Shenzhen Third People's Hospital as the main center, the project is a charitable initiative initiated by the Beijing Chen Jumei Foundation. On November 10, 2023, the first day of the 2023 American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Dr. Hongfei Zhang's team from the Chen Jumei Medical Group presented the latest stage data of the "Sprout" project. The team's detailed introduction to the project and its progress is shared below.

AASLD 2023: 17 Must-See Studies

By Peter W. PENG 2023.12.21

From November 10th to 14th, the annualHepatology Digest conference, the American Association for the Study of Liver Diseases (AASLD) 2023 held in Boston, USA. This event gathers the latest academic developments, clinical research findings, and major academic presentations in the field of liver disease. The following is a summary of 17 highly anticipated studies scheduled for presentation at the AASLD 2023 conference.

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

By Peter W. PENG 2023.12.21

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.

AASLD Voice of China丨Dr. Fengmin Lu: A1762T/G1764A Mutation Promotes HBV Replication, HNF1α Holds Promise as a Novel Therapeutic Target

By Peter W. PENG 2023.12.21

From November 10th to 14th, the annual highlight of hepatology, the American Association for the Study of Liver Diseases (AASLD) 2023, was grandly held in Boston, USA. With over 200 abstracts from Chinese experts and scholars selected for oral presentations or poster sessions, the achievements were commendable. Congratulations to all! Dr. Fengmin Lu's team from Peking University has three contributions to this event (1 oral presentation and 2 posters). Today, we'll share insights from one of the posters presented on the first day, November 10th, revealing the team's academic prowess. The research discovered that the A1762T/G1764A mutation, by affecting the HBV transcriptome, can promote HBV replication (Abstract Number: 1514-C).

AASLD Voice of China | Peking University Hepatology Institute Shines with 10 Achievements at AASLD 2023

By Peter W. PENG 2023.12.21

From November 10th to 14th, the annual international event in hepatology—the American Association for the Study of Liver Diseases (AASLD) 2023—was grandly held in Boston, USA. According to incomplete statistics, more than 200 abstracts from Chinese experts and scholars were selected for oral presentations or poster exchanges at this conference, achieving fruitful results. Congratulations are extended here! The Beijing University People's Hospital and Peking University Hepatology Institute team achieved 1 oral and 9 poster presentations on scientific research in the fields of hepatic encephalopathy, fatty liver, hepatitis C, hepatitis B, and liver cancer. Some research abstracts are shared below, and "Hepatology Digest" takes you to appreciate the team's excellence.

AASLD Review | New Therapies for Hepatitis B: Vebicorvir, Selgantolimod, Bepirovirsen, Therapeutic Vaccines, and More

By Mourabit Halima 2023.12.21

Currently, some patients with chronic hepatitis B (CHB) can achieve clinical cure through interferon-based antiviral treatment. To pursue clinical cure for a larger population, there is a flurry of activity in the development of new drugs. Six studies on new therapies for hepatitis B were selected for presentation at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, to be discussed in the "Hepatitis B: New Therapies for HBV and HDV" session. Hepatology Digest has compiled this information for interested readers, and the session is scheduled for online access on November 12th at 8:30 AM local time.

AASLD Review | Emerging Therapies for Metabolism-Related Fatty Liver Disease: Ecolgnetide, Saroglitazar, Retatrutide, etc.

By Peter W. PENG 2023.12.20

Metabolism-related fatty liver disease (MAFLD) has become the leading cause of global chronic liver disease, yet there are currently no targeted and effective treatments. In recent years, the development of new drugs for MAFLD and metabolism-related fatty liver hepatitis (MASH) has been a mix of optimism and concern. The 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting has selected six studies on novel MAFLD therapies from numerous abstract submissions. "Novel Therapeutic Approaches for MASH" will showcase relevant content, and interested readers can tune in on November 13th at 8:30 AM local time.

Dr. Chao Wu and Dr. Jie Li’s Team at Nanjing Drum Tower Hospital Focus on Non-invasive Diagnosis, Risk Factors, and Treatment Management of Hepatitis

By Peter W. PENG 2023.12.20

Hepatitis B virus (HBV) infection is a widespread global health issue. According to the World Health Organization, as of 2019, approximately 296 million people globally suffer from chronic HBV infection, with around 1.5 million new infections annually, leading to 820,000 deaths due to HBV-related complications. Data from the Chinese Center for Disease Control and Prevention indicates that around 86 million people in China have chronic HBV infection. Simultaneously, with changes in lifestyle and dietary habits, metabolic-associated fatty liver disease (MAFLD) has become the most common chronic liver disease globally, affecting approximately one-third of the world's population. In Asia, the prevalence of MAFLD has been steadily rising, increasing from 25.28% between 1999 and 2005 to 33.90% between 2012 and 2017.

AASLD Hot Topic | Dr. Zhihong Liu of Southern Hospital: Hepatitis B Expanded Treatment, Simplified Treatment, and Progress in Functional Cure Drugs Deserve Attention

By Mourabit Halima 2023.12.20

The AASLD (American Association for the Study of Liver Diseases) 2023 conference was held in Boston, USA, from November 10th to 14th, marking a significant event in the field of hepatology. Hepatology Digest's reporting team was fortunate to invite Dr. Zhihong Liu from the Department of Infectious Diseases and Hepatology at Southern Hospital of Southern Medical University to share insights from the AASLD and discuss the work presented by his team at the conference, along with their learning experiences.